The Bone Marrow Pathology Group (BMPG) recently held their annual meeting in New York, NY on September 11, 2015. The event, which was hosted by Dr. Attilio Orazi, took place in the Department of Pathology and Laboratory Medicine at WCMC.
The BMPG members include Drs. John Anastasi, Daniel Arber, Adam Bagg, Carlos Bueso-Ramos, Kathryn Foucar, Tracy George, Robert Hasserjian, Eric Hsi, William Morice, Attilio Orazi, LoAnn Peterson and Sa Wang.
Front row left to right: Carlos Bueso-Ramos (MD Anderson), Eric Hsi (Cleveland Clinic), Kathryn Foucar (University of New Mexico), Sa Wang (MD Anderson), Robert Hasserjian (Massachusetts General Hospital), Attilio Orazi (Weill Cornell Medical College), and Bill Morice (Mayo Clinic Minnesota).
Rear row left to right: Daniel Arber (Stanford University), Tracy George (University of New Mexico) and Adam Bagg (University of Pennsylvania).
The Bone Marrow Pathology Group discussed ongoing project and planned new studies. The group activity has resulted in several high profile publications and meeting presentations in recent years.
The Bone Marrow Pathology Group will hold their next annual meeting in Houston, TX in September 2016.
Peer Reviewed Publications:
- Rogers HJ, Vardiman JW, Anastasi J, Raca G, Savage NM, Cherry AM, Arber D, Moore E, Morrissette JJ, Bagg A, Liu YC, Mathew S, Orazi A, Lin P, Wang SA, Bueso-Ramos CE, Foucar K, Hasserjian RP, Tiu RV, Karafa M, Hsi ED. Complex or monosomal karyotype and not blast percentage are associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): A bone marrow pathology group study. Haematologica. 2014 May:99(5):821-9. 2014 Jan 24.
- Hasserjian RP, Campigotto F, Klepeis, V, Fu B, Wang SA, Bueso-Ramos C, Cascio MJ, Rogers HJ, Hsi ED, Soderquist C, Bagg A, Yan J, Ochs RC, Orazi A, Moore F, Mahmoud A, George TI, Foucar K, Odem J, Booth C, Morice W, DeAngelo DJ, Steensma D, Stone RM, Neuberg D, Arber DA. De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with ≥30% blasts in older adults: a Bone Marrow Pathology Group study. American Journal of Hematology 2014;89:E193-199.
- Wang SA, Hasserjian RP, Fox PS, Rogers HJ, Geyer JT, Chabot-Richards D, Weinzierl E, Hatem J, Jaso J, Kanagal-Shamanna R, Stingo FC, Patel KP, Mehrotra M, Bueso-Ramos C, Young KH, Dinardo CD, Verstovsek S, Tiu RV, Bagg A, Hsi ED, Arber DA, Foucar K, Luthra R, Orazi A. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. Blood. 2014 Apr 24;123(17):2645-51. doi: 10.1182/blood-2014-02-553800. Epub 2014 Mar 13. PubMed PMID: 24627528; PubMed Central PMCID: PMC4067498.
- Hasserjian RP, Campigotto F, Klepeis V, Fu B, Wang SA, Cascio MJ, Rogers HJ, Hsi ED, Soderquist C, Bagg A, Yang J, Ochs RC, Orazi A, Foucar K, Moor F, Mahmoud A, George TI, DeAngelo DJ, Steensma DP, Stone RM, Neuberg DS, Arber DA. Refractory anemia with excess blasts in transformation (acute myeloid leukemia with 20-29% blasts) in older adults is less aggressive than acute myeloid leukemia with ≥30% blasts. Blood 2013;122:1345.